VEOZAH

USDailyMed:Fezolinetant AU:B3 G02CX06(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone 1629229-37-3 117604931 DB15669 58828046 83VNE45KXX D11976 CHEBI:229236 ChEMBL3608680 DTXSID601103615 Interactive image C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1Key:PPSNFPASKFYPMN-SECBINFHSA-N Fezolinetant, sold under the brand nameVeozah, among others, is amedicationused for the treatment ofhot flashes(vasomotor symptoms) due tomenopause.It is asmall-molecule,selectiveneurokinin-3(NK3)receptor antagonisttakenby mouth.It was developed byAstellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017. The most common side effects of fezolinetant include abdominal pain, diarrhea,insomnia, back pain, hot flush, andelevated hepatic transaminases. Fezolinetant was approved for medical use in the United States in May 2023,and it was approved in theEuropean Unionin December 2023.Fezolinetant is the first NK3receptor antagonist approved by the USFood and Drug Administration(FDA) to treat moderate to severe hot flashes from menopause.The FDA considers it to be afirst-in-class medication.